Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
The present invention relates a new process to synthesize 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine (AL3818). A stable crystalline form of A13818 has been prepared. Salts and their crystalline forms of AL3818 have been also prepared. Anti-cancer and optometric activities of AL3818 and its salts have been further tested. New process has been outlined in Scheme I.
1. A process to synthesize 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-quinolin-7-yloxy)methyl)cyclopropanamine (AL3818) by condensing intermediate (X1) with (Y1) in a solvent at the presence of KI or NaI, or intermediate (X2) with (Y2) to form intermediate (Z) which is deprotected to give the final compound (AL3818) in Scheme I
Wherein
R is selected from H and C 1 -C 6 alkoxy; R is further selected from H and —OMe.
2. The process to synthesize 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine (AL3818) according to claim 1 where AL3818 can be prepared according to Process A2 when R is 4-OMe by deprotecting intermediate (Z-2) with TFA in DCM at 0° C.-30° C. for 1-24 hours (Z-2) can be prepared by reacting intermediate (X1) with (Y1-2) at the presence of KI or NaI with K 2 CO 3 in acetone or DMF at a temperature of 60° C.-160° C. for 2-24 hours
3. The process to synthesize 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine (AL3818) according to claim 2 where (Z-1) is prepared according to Process B1 by reacting intermediate (X2-1) with (Y2) in pyridine or lutidine at a temperature of 60° C.-160° C. for 1-12 hours
4. The process to synthesize 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine (AL3818) according to claim 3 where (Z-2) is prepared according to Process B2 by reacting intermediate (X2-2) with (Y2) in pyridine or lutidine at a temperature of 60° C.-160° C. for 1-12 hours
5. The process to prepare intermediate (Z) according to claim 1 , wherein R is H or —OMe, KI is used according to first step of Process A1 and A2 with DMF at 80° C. and wherein Lutidine is used according to first step of Process B1 and B2 at 135° C.
6. The process to synthesize 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine (AL3818) according to claim 1 , wherein R is H, HCOONH4/Pd/C is used for the deprotection step at 45° C.; wherein R is —OMe, DCM/TFA (10/1) is used for the deprotection step at 25° C.
7. A salt of 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)-methyl)-cyclopropanamine, wherein the salt is selected from: a bishydrochloride acid salt, a bishydrochloridehydrate acid salt, a bismaleic acid salt and a succinic acid salt.
8. A crystalline form of the bishydrochloride salt of 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-quinolin-7-yloxy)methyl)cyclopropanamine according claim 7 wherein the crystalline form exhibits a XRPD having 21 of the following characteristic peaks with intensity % greater than 10% expressed in d values and angles as follows:
NO.
Angle
d value
Intensity (%)
1
7.640
11.56173
19.5
2
8.642
10.22328
20
3
9.361
9.43969
13.3
4
10.091
8.75881
100.0
5
13.740
6.43957
26.4
6
14.479
6.11252
54.7
7
15.186
5.82962
10.1
8
15.766
5.61643
20.3
9
17.206
5.14957
7.4
10
18.569
4.77448
18.6
11
19.271
4.60215
11.0
12
20.041
4.42696
49.5
13
22.211
3.99909
58.4
14
22.814
3.89483
11.2
15
23.398
3.79886
11.6
16
24.455
3.63702
76.6
17
25.524
3.48708
34.6
18
26.703
3.33576
21.7
19
27.337
3.25978
18.4
20
28.061
3.17732
18.5
21
28.801
3.09732
6.3
22
29.845
2.99133
13.8
23
31.331
2.85271
7.1
24
31.621
2.82721
9.5
25
32.840
2.72504
10.5
26
33.714
2.65632
3.8
27
38.348
2.34534
9.6.
9. A crystalline form of the bishydrochloridehydrate acid salt of 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-quinolin-7-yloxy)methyl)cyclopropanamine according claim 7 wherein the crystalline form exhibits a XRPD having 9 of the following characteristic peaks with intensity % greater than 10% expressed in d values and angles as follows:
NO.
Angle
d value
Intensity (%)
1
5.506
16.03679
28.0
2
6.817
12.95694
100
3
8.087
10.92445
29.9
4
9.766
9.04936
20.6
5
13.318
6.64283
22.3
6
14.332
6.17523
7.0
7
16.159
5.48067
15.7
8
19.474
4.55451
8.8
9
20.920
4.24296
6.5
10
20.920
3.87231
28.2
11
25.087
3.54678
20.2
12
25.874
3.44064
22.7.
10. A crystalline form of the bismaleic acid salt of 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-quinolin-7-yloxy)methyl)cyclopropanamine according claim 7 wherein the crystalline form exhibits a XRPD having pattern comprising 22 of the following characteristic peaks with intensity % greater than 10% expressed in d values and angles as follows:
NO.
Angle
d value
Intensity (%)
1
6.716
13.14986
29.7
2
8.816
10.02189
34.3
3
9.743
9.07069
15.3
4
10.033
8.80923
21.4
5
11.777
7.50803
21.2
6
13.418
6.59342
6.2
7
14.816
5.97445
11.0
8
16.089
5.50434
9.5
9
16.801
5.27279
24.5
10
17.360
5.10409
87.9
11
17.179
5.15755
70.7
12
18.190
4.87308
20.2
13
18.704
4.74028
16.7
14
19.296
4.59623
5.0
15
19.920
4.45371
12.6
16
20.824
4.26227
65.5
17
21.457
4.13785
100.0
18
22.411
3.96393
4.5
19
22.876
3.88434
5.8
20
23.204
3.83021
19.0
21
23.622
3.76332
78.4
22
24.418
3.64247
6.3
23
26.140
3.40621
87.0
24
26.958
3.30469
26.5
25
27.383
3.25443
61.3
26
28.154
3.16697
41.5
27
29.554
3.02013
6.8
28
30.611
2.91815
23.7
29
31.373
2.84906
14.3
30
33.457
2.67620
6.7
31
34.541
2.59465
2.8
32
35.137
2.55199
3.8
33
35.734
2.51067
2.5
34
37.129
2.41949
8.6
35
39.704
2.26833
3.9.
11. A crystalline form of the succinic acid salt of 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-quinolin-7-yloxy)methyl)cyclopropanamine according claim 7 wherein the crystalline form exhibits a XRPD having 7 of the following characteristic peaks with intensity % greater than 10% expressed in d values and angles as follows:
NO.
Angle
d value
Intensity (%)
1
5.765
15.31849
12.9
2
8.038
10.98994
7.4
3
11.639
7.59700
27.7
4
12.9506
6.83065
100
5
16.1415
5.48683
18.0
6
17.4835
5.06846
18.7
7
18.385
4.82175
17.8
8
19.394
4.57325
1.1
9
20.756
4.27609
13.4
10
22.034
4.03092
2.8
11
23.167
3.83630
1.8
12
24.085
3.69200
16.9
13
24.485
3.63268
14.6
14
25.737
3.45874
13.7
15
28.621
3.11637
6.4
16
29.255
3.05025
22.1
17
31.357
2.85048
0.9
18
31.967
2.79743
2.1
19
35.630
2.51780
2.4.
12. A salt of 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)-cyclopropanamine according to claim 7 with DSC and TGA having following characteristics:
bishydrochloride acid salt with DSC Melting Range (Exo): 249-280 with Peak Temp=268° C. TGA demonstrating as an unsolvated material with weight loss at about 230° C. (between 225-235° C.), shown in FIG. 4 , FIG. 5 ;
bishydrochloridehydrate acid salt with DSC Melting Range (Exo): 207-260° C. with Peak Temp=226° C. TGA demonstrating 2.68% (˜3%, 1 water) weight loss till 120° C. (between 115-125° C.) and further weight loss at about 170° C. (between 165-175° C.), shown in FIG. 7 , FIG. 8 ;
bismaleic acid salt with DSC Melting Range (Endo): 165-202° C. with Peak Temp=183° C. TGA demonstrating as an unsolvated material with weight loss at about 160° C. (between 155-165° C.), shown in FIG. 10 , FIG. 11 ; or
succinic acid salt with DSC Melting Range: Melting Range (Endo): 176-202° C. with Peak Temp=198° C. TGA demonstrating as an unsolvated material with weight loss at about 180° C. (between 175-185° C.), shown in FIG. 13 , FIG. 14 .
13. A pharmaceutical composition comprising:
a bishydrochloride acid, bishydrochloridehydrate acid, bismaleic acid or succinic acid salt of 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine; and
a pharmaceutically acceptable carrier.
14. A method of treating a neoplastic disease, said method comprising administering a compound as defined in claim 7 to a subject in need thereof.
15. A method of treating as claimed in claim 14 , wherein the neoplastic disease is solid tumors, selected from lung, renal, colorectal, gastric, melanoma, head/neck, thyroid, pancreatic, liver, prostate, bladder, brain, sarcoma, breast, ovarian, cervical and endometrial cancers; and blood cancers, selected from ALL, CLL, AML, CML and Multiple Myeloma.
16. A method of treating as claimed in claim 14 , wherein the combing chemotherapy agents are selected from platinum based or taxane based agents.
17. A method of treating as claimed in claim 14 , wherein the combing chemotherapy agent selected from the group consisting of cisplatin, carboplatin, paclitaxel or cisplatin/paclitaxel or carboplatin/paclitaxel.
18. A method of treating as claimed in claim 14 , wherein the combining immunotherapy agents are selected from nivolumab, pembrolizumab, ipilimumab, blinatumomab, elotuzumab, daratumumab, talimogene laherparepvec based agents.
19. A method of treating an optometric disease, said method comprising administering a compound as defined in claim 7 .
20. A method of treating as claimed in claim 19 , wherein an optometric disease is AMD and the combing anti-VEGF antibody is ranibizumab, or the VEGF trap is aflibercep.
21. A method of treating a neoplastic disease, said method comprising administering a pharmaceutical composition comprising the compound as defined claim 7 and a pharmaceutically acceptable excipient to a subject in need thereof.
22. A method of treating a neoplastic disease, said method comprising administering a pharmaceutical composition comprising the compound as defined claim 7 with chemotherapy agents or immunotherapy agents to a subject in need thereof.
23. A method of treating an optometric disease, said method comprising administering a pharmaceutical composition comprising the compound as defined claim 7 and a pharmaceutically acceptable excipient to a subject in need thereof.
24. A method of treating an optometric disease, said method comprising administering a pharmaceutical composition comprising the compound as defined claim 7 with an anti-VEGF antibody or VEGF trap to a subject in need thereof.